Apixaban DOAC selectively inhibits factor Xa.
– Indicated for NVAF patients for prophylaxis from stroke and systemic embolism
– Used for VTE treatment and prophylaxis from VTE
Apixatrack available with 2 concentrations
Apixatrack 5 mg (10 tablets)
Apixatrack 2.5 mg (20 tablets)